Search Patents
  • BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
    Publication number: 20240117010
    Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: April 11, 2024
    Applicant: Navigo Proteins GmbH
    Inventors: Mathias Kahl, Erik Fiedler, Eva Bosse-Doenecke, Anja Katzschmann, Hanna Bobolowski, Jonathan Lotze, Maren Meysing
  • BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
    Publication number: 20230272050
    Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 31, 2023
    Applicant: Navigo Proteins GmbH
    Inventors: Mathias Kahl, Erik Fiedler, Eva Bosse-Doenecke, Anja Katzschmann, Hanna Bobolowski, Jonathan Lotze, Maren Meysing
  • DJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE
    Publication number: 20240277832
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 22, 2024
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF
    Publication number: 20240309072
    Abstract: The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-COV and/or SARS-COV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-COV and SARS-COV-2 infections, such as COVID-19.
    Type: Application
    Filed: February 27, 2024
    Publication date: September 19, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nianshuang WANG, Yang SHEN, Alina BAUM, Christos KYRATSOUS, Chia-Yang LIN
  • Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof
    Publication number: 20230203101
    Abstract: The present invention relates to a recombinant spike protein of the COVID-19 virus forming a trimer and a method for mass-producing the recombinant spike protein, and more specifically to a method for designing a recombinant gene expressing a recombinant spike protein of the COVID-19 virus forming a trimer for the purposes of enhancing immunogenicity and effective antigen delivery, and a method for mass-producing the recombinant spike protein in plants.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 29, 2023
    Applicants: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KOREA NATIONAL INSTITUTE OF HEALTH, BIOAPPLICATIONS INC
    Inventors: In Hwan HWANG, Shijian SONG, Rezaul Islam Khan MD, Haiping DIAO, Eun Ju SOHN, Bo Hwa CHOI, Jang Hoon CHOI, Eun Young JANG, Young Jae LEE
  • MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF
    Publication number: 20240287162
    Abstract: The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
    Type: Application
    Filed: February 27, 2024
    Publication date: August 29, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nianshuang WANG, Yang SHEN, Alina BAUM, Christos KYRATSOUS, Chia-Yang LIN, Tri NGUYEN
  • MODIFIED SPIKE PROTEIN AND METHOD OF TREATMENT
    Publication number: 20220356212
    Abstract: In one embodiment, the present specification discloses a modified spike (S) protein comprising of SEQ ID NO: 2, the modified spike protein encoded by a gene sequence of SEQ ID NO: 1, and methods of using the modified spike protein as disclosed herein.
    Type: Application
    Filed: March 25, 2022
    Publication date: November 10, 2022
    Applicant: Nanogen Pharmaceutical Biotechnology JSC
    Inventors: Nhan Ho, Si Minh Do, Bruce May
  • RECOMBINANT SARS-COV-2 SPIKE PROTEIN AND USES THEREOF
    Publication number: 20240210415
    Abstract: Provided herein are recombinant SARS-CoV-2 spike proteins, cells producing such proteins, and kits comprising such proteins. Also provided herein are compositions comprising recombinant SARS-CoV-2 spike proteins and methods of detecting antibodies using such SARS-CoV-2 spike proteins.
    Type: Application
    Filed: March 17, 2021
    Publication date: June 27, 2024
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Florian KRAMMER, Adolfo FIRPO-BETANCOURT, Carlos CORDON-CARDO, Damodara Rao MENDU, Viviana SIMON, Fatima AMANAT, Daniel STADLBAUER
  • INFECTIOUS BRONCHITIS VIRUS (IBV) SPIKE PROTEIN AS SUBUNIT VACCINE
    Publication number: 20140127264
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Application
    Filed: March 1, 2012
    Publication date: May 8, 2014
    Inventors: Hèélne Verheije, Carla Christina Schrier
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20150337029
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • ENGINEERED SPIKE PROTEINS OF HANTAVIRUSES AND USES THEREOF
    Publication number: 20210000940
    Abstract: Hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike to enable their use as immunogens in next-generation vaccine design. The spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. Also, spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts. The spike proteins can be soluble Gn/Gc ectodomains in solution and/or incorporated as (Gn/Gc)n hetero-oligomers onto virus-like particles (VLPs) and/or used for pseudotyping virus vectors and/or form part of a stabilized recombinant virus. The spike proteins can be used to select ligands and/or can be used for preventing or treating infections by one or more hantaviruses.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 7, 2021
    Applicants: FUNDACIÓN CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole TISCHLER, Eduardo Andrés BIGNON SILVA, Félix Augusto REY, Pablo GUARDADO CALVO
  • Infectious bronchitis virus (IBV) spike protein as subunit vaccine
    Patent number: 9597390
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: March 21, 2017
    Assignees: Utrech University, Intervet Inc.
    Inventors: Hélène Verheije, Carla Christina Schrier
  • Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use
    Patent number: 11911461
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome. The adjuvanted protein vaccines are suitable for subcutaneous administration. Also disclosed herein are modified spike protein sequences containing SARS-CoV-2 variant C.1.2 modified S1 Spike proteins and methods of use of the vaccines and sequences.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: February 27, 2024
    Assignee: D4 Labs, LLC
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • DNA encoding the Canine coronavirus spike protein
    Patent number: 5661006
    Abstract: The invention is related to a nucleic acid sequence &coding a Canine coronavirus (CCV) spike protein. Such a protein can be used for the immunization of dogs against CCV infection. The nucleic acid sequence encoding the CCV spike protein can be applied for the preparation of the spike protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: August 26, 1997
    Assignee: Akzo Nobel N.V.
    Inventors: Thomas David Kay Brown, Brian Colin Horsburgh
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20190351049
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Inventors: Christos KYRATSOUS, Neil STAHL, Sumathi SIVAPALASINGAM
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20170340728
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 30, 2017
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human antibodies to middle east respiratory syndrome—coronavirus spike protein
    Patent number: 9718872
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 1, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
    Patent number: 10406222
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Stabilized recombinant hantaviral spike proteins comprising mutations in Gc
    Patent number: 11723968
    Abstract: The present invention describes specific engineering of the hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike with the purpose of using them as immunogens in next-generation vaccine design. Said spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. It also involves spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 15, 2023
    Assignees: FUNDACION CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole Tischler, Eduardo Andrés Bignon Silva, Félix Augusto Rey, Pablo Guardado Calvo
  • SARS-COV-2 spike protein binding molecule and application thereof
    Publication number: 20230331822
    Abstract: Provided are a SARS-COV-2 spike protein binding molecule and an application thereof. The binding molecule may specifically bind to a SARS-COV-2 spike protein and contains at least one immunoglobulin single variable domain, may effectively block the binding of the SARS-COV-2-Spike protein to an ACE2 receptor of a human cell, thereby blocking the infection of the cell with SARS-COV-2 and inhibiting SARS-COV-2 infection and amplification.
    Type: Application
    Filed: March 8, 2021
    Publication date: October 19, 2023
    Inventor: Junfang ZHANG
Narrow Results

Filter by US Classification